文献速递艾滋病与性传播感染

抗PD-1与抗CTLA-4对接受抗逆转录病毒治疗的HIV合并癌症患者HIV储存库的影响:AIDS恶性肿瘤联盟095研究

Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究为AIDS恶性肿瘤联盟095研究的子研究,纳入40例接受抗逆转录病毒治疗且病毒抑制的HIV合并晚期恶性肿瘤患者,分别接受纳武利尤单抗单药或联合伊匹木单抗。

要点

  • 抗PD-1单药未改变HIV潜伏或潜伏储存库。
  • 抗PD-1联合抗CTLA-4首次剂量后细胞相关未剪接HIV RNA中位数增加1.44倍。
  • 联合治疗未显著降低复制 competent HIV细胞频率,仅个别病例下降。

核心结论

  • 抗PD-1单药对HIV潜伏或潜伏HIV储存库无影响。
  • 抗PD-1联合抗CTLA-4可诱导细胞相关未剪接HIV RNA适度增加,并可能潜在清除含复制 competent HIV的细胞。

研究设计与样本

  • AIDS恶性肿瘤联盟095研究的子研究。
  • 40例接受抗逆转录病毒治疗且病毒抑制的HIV合并晚期恶性肿瘤患者,33例接受纳武利尤单抗,7例接受纳武利尤单抗联合伊匹木单抗。
  • 在首次和第四次免疫检查点阻断剂量前及后1天和7天采集样本,定量细胞相关未剪接HIV RNA和HIV DNA,第一治疗周期定量血浆HIV RNA,部分样本行定量病毒生长试验。

主要发现

  • 纳武利尤单抗单药治疗期间细胞相关未剪接HIV RNA无变化。
  • 含复制 competent HIV的细胞频率未下降,但2例接受联合免疫检查点阻断且有纵向定量病毒生长试验的个体分别检测到较基线下降97%和64%。

临床怎么用

  • 抗PD-1单药治疗对HIV储存库无显著影响,临床决策时不应期待其降低HIV储存库。
  • 抗PD-1联合抗CTLA-4可能短暂增加细胞相关未剪接HIV RNA,需监测HIV RNA及储存库变化。
  • 联合治疗潜在清除复制 competent HIV细胞的作用需进一步研究验证。

局限性

  • 样本量较小,联合治疗组仅7例。
  • 纵向定量病毒生长试验数据仅来自2例联合治疗患者。
  • 研究对象为HIV合并晚期恶性肿瘤患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer. METHODS: This was a substudy of the AIDS Malignancy Consortium 095 Study. ART-suppressed PLWH with advanced malignancies were assigned to nivolumab (anti-PD-1) with or without ipilimumab (anti-CTLA-4). In samples obtained preinfusion and 1 and 7 days after the first and fourth doses of immune checkpoint blockade (ICB), we quantified cell-associated unspliced (CA-US) HIV RNA and HIV DNA. Plasma HIV RNA was quantified during the first treatment cycle. Quantitative viral outgrowth assay (QVOA) to estimate the frequency of replication-competent HIV was performed before and after ICB for participants with samples available. RESULTS: Of 40 participants, 33 received nivolumab and 7 nivolumab plus ipilimumab. Whereas CA-US HIV RNA did not change with nivolumab monotherapy, we detected a median 1.44-fold increase (interquartile range, 1.16-1.89) after the first dose of nivolumab and ipilimumab combination therapy (P = .031). There was no decrease in the frequency of cells containing replication-competent HIV, but in the 2 individuals on combination ICB for whom we had longitudinal QVOA, we detected decreases of 97% and 64% compared to baseline. CONCLUSIONS: Anti-PD-1 alone showed no effect on HIV latency or the latent HIV reservoir, but the combination of anti-PD-1 and anti-CTL-4 induced a modest increase in CA-US HIV RNA and may potentially eliminate cells containing replication-competent HIV. CLINICAL TRIALS REGISTRATION: NCT02408861.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rasmussen TA, Rajdev L, Rhodes A, et al. Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021. PMID: 33677480. doi:10.1093/cid/ciaa1530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。